as 01-21-2025 4:00pm EST
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Upcoming Earnings Alert:
Get ready for potential market movements as Dr. Reddy's Laboratories Ltd RDY prepares to release earnings report on 23 Jan 2025.
Founded: | 1984 | Country: | India |
Employees: | N/A | City: | N/A |
Market Cap: | 2.5B | IPO Year: | N/A |
Target Price: | $17.00 | AVG Volume (30 days): | 1.9M |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
EPS: | 0.76 | EPS Growth: | 4.63 |
52 Week Low/High: | $13.52 - $16.89 | Next Earning Date: | 01-23-2025 |
Revenue: | $3,579,112,656 | Revenue Growth: | 12.37% |
Revenue Growth (this year): | 16.39% | Revenue Growth (next year): | 8.74% |
RDY Breaking Stock News: Dive into RDY Ticker-Specific Updates for Smart Investing
TipRanks
a month ago
TipRanks
2 months ago
Insider Monkey
2 months ago
TipRanks
2 months ago
Business Wire
2 months ago
Business Wire
2 months ago
TipRanks
2 months ago
Zacks
2 months ago
The information presented on this page, "RDY Dr. Reddy's Laboratories Ltd - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.